mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? (Q38250176)

1 September 2017

1 reference

title

mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern? (English)

1 reference

1 September 2017

1 reference

Hallvard Holdaas

1 reference

1 September 2017

Luciano Potena

series ordinal

1 reference

1 September 2017

Faouzi Saliba

series ordinal

1 reference

1 September 2017

publication date

27 August 2014

1 reference

1 September 2017

published in

Transplantation Reviews

1 reference

1 September 2017

1 reference

1 September 2017

1 reference

1 September 2017

page(s)

93-102

1 reference

Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Cardiovascular complications after renal transplantation and their prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Incidence and predictors of myocardial infarction after kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Acute myocardial infarction and kidney transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Validation of cardiovascular risk scores in a liver transplant population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

OPTN/SRTR 2011 Annual Data Report: heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

ISHLT International Registry for Heart and Lung Transplantation--into the fourth decade, from strength to strength

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

The prognostic importance of modifiable risk factors after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Cardiovascular risk factors after liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Strategies for minimizing hyperlipidemia after cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Use of cardioprotective medications in kidney transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

The immunosuppressive agents rapamycin, cyclosporin A and tacrolimus increase lipolysis, inhibit lipid storage and alter expression of genes involved in lipid metabolism in human adipose tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Major involvement of mTOR in the PPARγ-induced stimulation of adipose tissue lipid uptake and fat accretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

The mammalian target of rapamycin regulates lipid metabolism in primary cultures of rat hepatocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Effects of sirolimus on lipids in renal allograft recipients: an analysis using the Framingham risk model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus immunosuppression in de novo heart transplant recipients: what does the evidence tell us now?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Improved renal function, with similar proteinuria, after two years of early tacrolimus withdrawal from a regimen of sirolimus plus tacrolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Conversion to everolimus in maintenance liver transplant patients: A multicenter, retrospective analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Selective clearance of macrophages in atherosclerotic plaques by autophagy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Aortic stiffness and central wave reflections predict outcome in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Aortic stiffness, kidney disease, and renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus prevents endomyocardial remodeling after heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Prognostic importance of renal function 1 year after heart transplantation for all-cause and cardiac mortality and development of allograft vasculopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

A drug safety evaluation of everolimus in kidney transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

m-TOR inhibitors: what role in liver transplantation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Everolimus in liver and lung transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Clinical recommendations for the use of everolimus in heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

mTOR inhibitor-associated proteinuria in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

Reducing the risks of cardiovascular disease in liver allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRRE.2014.08.003

10.1016/J.TRRE.2014.08.003

7 January 2021

Identifiers

DOI

1 reference

1 September 2017

1 reference